Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Open Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of DBC-664 in Adult Patients With Locally Advanced or Metastatic Solid Tumors

NCT07705035 is registered in ClinicalTrials.gov with Duboce Biopharmaceuticals, Inc. as lead sponsor.

NCT NCT07705035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07705035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Open Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of DBC-664 in Adult Patients With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Duboce Biopharmaceuticals, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
July 17, 2026
Completion date
April 1, 2030
Enrollment
210 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial adenocarcinoma, gastric/esophageal/gastroesophageal junction (gej) adenocarcinoma, lung adenocarcinoma, malignant germ cell tumor, ovarian adenocarcinoma, urothelial carcinoma